4 November 2026

ASX Announcement

Pre-trial surgeries commenced for NHP cohorts in USAMRIID Marburg study ahead of dosing in December

- **USAMRIID commences scheduled surgical preparations for 22 non-human primates (NHPs) ahead of Galidesivir Marburg dose optimisation study**
- **Procedures form part of the established study protocol and will facilitate targeted drug delivery and monitoring during the study**
- **Following surgeries and recovery, dosing expected to begin early December CY26 in accordance with the planned timetable**
- **Study designed to identify optimal Galidesivir dosing regimen to inform planned pivotal confirmatory efficacy study under the US FDA Animal Rule pathway**

For personal use only

MELBOURNE Australia, 4 November 2026: Australian antiviral drug development and biodefence company, Island Pharmaceuticals Ltd (**ASX: ILA**; **Island** or **the Company**) is pleased to advise that scheduled surgical preparations for the 22 non-human primates (NHPs) allocated to its upcoming Galidesivir dose optimisation study targeting Marburg Virus Disease (MVD) have commenced at the United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Maryland, USA.

The commencement of these procedures represents a significant operational milestone for Island, following the successful completion of NHP screening and preparation activities (refer ASX announcement: 19 October 2026). It marks further progress towards the commencement of dosing, which remains on track for this quarter.

The procedures form part of the established study protocol and are designed to facilitate Day 0 Marburg infection and support the frequent collection of study data. Surgical preparations are expected to be completed over the coming weeks, after which the NHPs will undergo a scheduled recovery period immediately prior to dosing.

Importantly, these activities are proceeding in line with the established study schedule, with Galidesivir dosing remaining on track to commence during in early December CY26.

The USAMRIID study will evaluate Galidesivir against the Angola strain of Marburg virus, with the objective of identifying an effective dosing regimen to inform the design of Island's planned pivotal efficacy study.

The study will involve 20 NHPs, with two additional animals available as reserves, and will assess Galidesivir administered at varying dose levels and treatment initiation timepoints. Data generated will support the Company's ongoing development program under the US Food and Drug Administration's (FDA) Animal Rule pathway, which provides a potential regulatory approval pathway where human efficacy studies are not ethical or feasible.

Management commentary:

CEO and Managing Director, Dr David Foster said: *"The commencement of surgical preparations at USAMRIID is another important milestone for Island and demonstrates the continued progress being made towards the start of our Galidesivir dose optimisation study.*

"Following the successful screening and preparation of all 22 NHPs earlier this month, we are pleased to see the program advance into this next phase, the final step before the study begins.

"Importantly, these are standard procedures required to support the planned dosing and monitoring activities, and based on the current timeline, everything continues to progress in line with our expected timetable.

"With dosing and topline results remaining on track for this quarter, we are approaching a significant stage in the development of Galidesivir. The data generated from this study will play an integral role in informing our pivotal efficacy program and progressing our broader regulatory strategy for Marburg."

Next steps:

Following completion of the scheduled surgical procedures and recovery period, the USAMRIID study team will progress the NHPs into commencement of Galidesivir dosing during early December CY26.

The study will assess survival at 28 days following Marburg Angola exposure, supported by additional measures including viral load, clinical observations and pharmacokinetic data.

The results will inform dose selection and the design of Island's planned pivotal confirmatory efficacy study, representing a crucial step towards advancing Galidesivir through the FDA Animal Rule approval pathway.

Island will continue to provide updates as material study milestones are achieved.

- Ends -

Approved for release to the ASX by:
The Board of Island Pharmaceuticals Limited
info@islandpharmaceuticals.com

Investors and media, for further information, please contact:

Henry Jordan
Six Degrees Investor Relations
+61 (0) 431 271 538
henry.jordan@sdir.com.au

For personal use only

About Island Pharmaceuticals

Island (ASX: ILA) is focused on areas of unmet need for drugs that can address urgent viral diseases, public health or biosecurity threats. The Company is executing a dual development strategy for its assets, ISLA-101 and Galidesivir.

ISLA-101 has a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases. Galidesivir is a clinical-stage antiviral molecule with a broad spectrum of activity in over 20 RNA viruses, including high-priority threats such as Ebola, Marburg, MERS, Zika and Yellow fever – viruses with significant unmet medical needs and that may contribute to national security threats.

Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.

Visit www.islandpharmaceuticals.com for more on Island.

For personal use only